{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:21:53Z","timestamp":1791393713939,"version":"4.3.3"},"reference-count":93,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","gastro.theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology Clinics of North America"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.gtc.2017.05.013","type":"journal-article","created":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T22:48:18Z","timestamp":1503701298000},"page":"603-626","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease"],"prefix":"10.1016","volume":"46","author":[{"given":"Parakkal","family":"Deepak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Sandborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.gtc.2017.05.013_bib1","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMra0804647","article-title":"Inflammatory bowel disease","volume":"361","author":"Abraham","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"7152","key":"10.1016\/j.gtc.2017.05.013_bib2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature06005","article-title":"Unravelling the pathogenesis of inflammatory bowel disease","volume":"448","author":"Xavier","year":"2007","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.gtc.2017.05.013_bib3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nri1001","article-title":"Interleukin-12 and the regulation of innate resistance and adaptive immunity","volume":"3","author":"Trinchieri","year":"2003","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"10.1016\/j.gtc.2017.05.013_bib4","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1084\/jem.170.3.827","article-title":"Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes","volume":"170","author":"Kobayashi","year":"1989","journal-title":"J\u00a0Exp Med"},{"issue":"24","key":"10.1016\/j.gtc.2017.05.013_bib5","doi-asserted-by":"crossref","first-page":"14002","DOI":"10.1073\/pnas.93.24.14002","article-title":"A\u00a0functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits","volume":"93","author":"Presky","year":"1996","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"11","key":"10.1016\/j.gtc.2017.05.013_bib6","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.4049\/jimmunol.168.11.5699","article-title":"A\u00a0receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R","volume":"168","author":"Parham","year":"2002","journal-title":"J\u00a0Immunol"},{"issue":"3","key":"10.1016\/j.gtc.2017.05.013_bib7","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1074\/jbc.M207577200","article-title":"Interleukin-23 promotes a distinct CD4 T\u00a0cell activation state characterized by the production of interleukin-17","volume":"278","author":"Aggarwal","year":"2003","journal-title":"J\u00a0Biol Chem"},{"issue":"7","key":"10.1016\/j.gtc.2017.05.013_bib8","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nbt.1903","article-title":"Therapeutic targeting of the IL-12\/23 pathways: generation and characterization of ustekinumab","volume":"29","author":"Benson","year":"2011","journal-title":"Nat Biotechnol"},{"issue":"5","key":"10.1016\/j.gtc.2017.05.013_bib9","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1084\/jem.182.5.1281","article-title":"Antibodies to interleukin 12 abrogate established experimental colitis in mice","volume":"182","author":"Neurath","year":"1995","journal-title":"J\u00a0Exp Med"},{"issue":"2","key":"10.1016\/j.gtc.2017.05.013_bib10","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.immuni.2006.05.017","article-title":"Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology","volume":"25","author":"Uhlig","year":"2006","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.gtc.2017.05.013_bib11","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.4049\/jimmunol.177.5.2760","article-title":"Cutting edge: IL-23 cross-regulates IL-12 production in T\u00a0cell-dependent experimental colitis","volume":"177","author":"Becker","year":"2006","journal-title":"J\u00a0Immunol"},{"issue":"6","key":"10.1016\/j.gtc.2017.05.013_bib12","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1053\/j.gastro.2011.02.016","article-title":"Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases","volume":"140","author":"Strober","year":"2011","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.gtc.2017.05.013_bib13","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.2174\/13894501113146660229","article-title":"Anti-IL-12\/23 in Crohn's disease: bench and bedside","volume":"14","author":"Niederreiter","year":"2013","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.gtc.2017.05.013_bib14","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.2147\/DDDT.S102141","article-title":"Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy","volume":"10","author":"Deepak","year":"2016","journal-title":"Drug Des Devel Ther"},{"issue":"20","key":"10.1016\/j.gtc.2017.05.013_bib15","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1056\/NEJMoa033402","article-title":"Anti-interleukin-12 antibody for active Crohn's disease","volume":"351","author":"Mannon","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.gtc.2017.05.013_bib16","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn's disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.gtc.2017.05.013_bib17","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","article-title":"A\u00a0randomized trial of Ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease","volume":"135","author":"Sandborn","year":"2008","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.gtc.2017.05.013_bib18","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/clpt.2008.170","article-title":"Monoclonal antibody pharmacokinetics and pharmacodynamics","volume":"84","author":"Wang","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.gtc.2017.05.013_bib19","unstructured":"Stelara(R) [package insert]. Horsham (PA): Janssen Biotech, Inc; 2016. Available at: http:\/\/www.stelarahcp.com\/pdf\/PrescribingInformation.pdf. Accessed February 20, 2017."},{"issue":"4","key":"10.1016\/j.gtc.2017.05.013_bib20","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/clpt.2011.328","article-title":"Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms","volume":"91","author":"Ordas","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.gtc.2017.05.013_bib21","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/0091270008329556","article-title":"Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12\/23p40, in patients with moderate to severe plaque psoriasis","volume":"49","author":"Zhu","year":"2009","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"17\u201318","key":"10.1016\/j.gtc.2017.05.013_bib22","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.drudis.2009.05.014","article-title":"Risk-based strategy for the assessment of pharmacokinetic drug-drug interactions for therapeutic monoclonal antibodies","volume":"14","author":"Zhou","year":"2009","journal-title":"Drug Discov Today"},{"issue":"9625","key":"10.1016\/j.gtc.2017.05.013_bib23","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"issue":"9625","key":"10.1016\/j.gtc.2017.05.013_bib24","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.gtc.2017.05.013_bib25","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1517\/14712591003724670","article-title":"The use of ustekinumab in autoimmune disease","volume":"10","author":"Ryan","year":"2010","journal-title":"Expert Opin Biol Ther"},{"issue":"9894","key":"10.1016\/j.gtc.2017.05.013_bib26","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.gtc.2017.05.013_bib27","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.gtc.2017.05.013_bib28","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1038\/ajg.2009.454","article-title":"Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease","volume":"104","author":"Toedter","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"20","key":"10.1016\/j.gtc.2017.05.013_bib29","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn's disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.gtc.2017.05.013_bib30","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/MIB.0000000000000720","article-title":"O-001 a multicenter, double-blind, placebo-controlled phase3 study of ustekinumab, a human IL-12\/23P40 mAB, in moderate-service Crohn's disease refractory to anti-TFNalpha: UNITI-1","volume":"22","author":"Sandborn","year":"2016","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"10.1016\/j.gtc.2017.05.013_bib31","first-page":"2","article-title":"OP054-LB4 A multicenter, double-blind, placebo-controlled Ph3 study of ustekinumab, a human monoclonal antibody to IL-12\/23p40, in patients with moderately-severely active Crohn\u2019s disease who are na\u00efve or not refractory to anti-TNFa: UNITI-2","volume":"3","author":"Feagan","year":"2015","journal-title":"United European Gastroenterol J"},{"issue":"4","key":"10.1016\/j.gtc.2017.05.013_bib32","first-page":"S157","article-title":"768 a phase 3 randomized, multicenter, double-blind, placebo-controlled study of ustekinumab maintenance therapy in moderate-severe Crohn's disease patients: results from IM-UNITI","volume":"150","author":"Sandborn","year":"2016","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.gtc.2017.05.013_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(14)61663-2","article-title":"Su1420 ustekinumab treatment for Crohn's disease in clinical practice: experience at a tertiary medical center","volume":"146","author":"Batista","year":"2014","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.gtc.2017.05.013_bib34","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.crohns.2014.06.005","article-title":"Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease\u2013the McGill experience","volume":"8","author":"Kopylov","year":"2014","journal-title":"J\u00a0Crohns Colitis"},{"issue":"2","key":"10.1016\/j.gtc.2017.05.013_bib35","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.cgh.2015.09.018","article-title":"Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn's disease refractory to anti-tumor necrosis factor agents","volume":"14","author":"Wils","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.gtc.2017.05.013_bib36","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1097\/MIB.0000000000000842","article-title":"Ustekinumab for the treatment of refractory Crohn's disease: the Spanish experience in a large multicentre open-label cohort","volume":"22","author":"Khorrami","year":"2016","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"10.1016\/j.gtc.2017.05.013_bib37","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/MIB.0000000000000624","article-title":"Patients with refractory Crohn's disease successfully treated with ustekinumab","volume":"22","author":"Harris","year":"2016","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10.1016\/j.gtc.2017.05.013_bib38","doi-asserted-by":"crossref","first-page":"S294","DOI":"10.14309\/00000434-201610001-00641","article-title":"Ustekinumab is effective for the induction and maintenance of response in Crohn\u2019s disease: a multi-center cohort study","volume":"111","author":"Ma","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.gtc.2017.05.013_bib39","doi-asserted-by":"crossref","first-page":"S334","DOI":"10.14309\/00000434-201610001-00745","article-title":"Ustekinumab use in Crohn\u2019s disease: real-life Canadian experience","volume":"111","author":"Greenup","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.gtc.2017.05.013_bib40","doi-asserted-by":"crossref","first-page":"S278","DOI":"10.14309\/00000434-201610001-00605","article-title":"Endoscopic healing in induction and maintenance with ustekinumab in the phase 3\u00a0UNITI Crohn\u2019s disease program","volume":"111","author":"Sandborn","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2017.05.013_bib41","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/ecco-jcc\/jjw019.027","article-title":"Pharmacokinetics and exposure-response relationships of intravenously administered ustekinumab during induction treatment in patients with Crohn's disease: results from the UNITI-1 and UNITI-2 studies","volume":"10","author":"Adedokun","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"issue":"4","key":"10.1016\/j.gtc.2017.05.013_bib42","first-page":"S408","article-title":"Sa1934 pharmacokinetics and exposure-response relationships of ustekinumab during IV induction and SC maintenance treatment of patients with Crohn's disease with ustekinumab: results from the UNITI-1, UNITI-2, and IM-UNITI studies","volume":"150","author":"Adedokun","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2017.05.013_bib43","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1093\/ecco-jcc\/jjw019.101","article-title":"Association of ustekinumab trough concentrations with clinical, biochemical, and endoscopic outcomes","volume":"10","author":"Battat","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"issue":"1","key":"10.1016\/j.gtc.2017.05.013_bib44","first-page":"S302","article-title":"Efficacy and safety of dose adjustment and delayed response to ustekinumab in moderate-severe Crohn\u2019s disease patients: results from the IM-UNITI maintenance study","volume":"111","author":"Sands","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.gtc.2017.05.013_bib45","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.gtc.2017.05.013_bib46","first-page":"S44","article-title":"P-122 comparative efficacy of pharmacological agents for moderate-severe Crohn's disease in patients with prior exposure to anti-TNF agents: a network meta-analysis","volume":"23","author":"Singh","year":"2017","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"10.1016\/j.gtc.2017.05.013_bib47","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjd.12214","article-title":"Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up","volume":"168","author":"Papp","year":"2013","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.gtc.2017.05.013_bib48","first-page":"706","article-title":"Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR)","volume":"14","author":"Papp","year":"2015","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"8","key":"10.1016\/j.gtc.2017.05.013_bib49","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1001\/jama.2011.1211","article-title":"Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials","volume":"306","author":"Ryan","year":"2011","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.gtc.2017.05.013_bib50","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJM199602223340803","article-title":"A\u00a0reversible posterior leukoencephalopathy syndrome","volume":"334","author":"Hinchey","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.gtc.2017.05.013_bib51","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/archdermatol.2011.161","article-title":"Reversible posterior leukoencephalopathy syndrome in a patient treated with ustekinumab: case report and review of the literature","volume":"147","author":"Gratton","year":"2011","journal-title":"Arch Dermatol"},{"issue":"9","key":"10.1016\/j.gtc.2017.05.013_bib52","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1474-4422(08)70173-X","article-title":"Repeated subcutaneous injections of IL12\/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study","volume":"7","author":"Segal","year":"2008","journal-title":"Lancet Neurol"},{"issue":"9","key":"10.1016\/j.gtc.2017.05.013_bib53","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.crohns.2014.02.004","article-title":"Demyelination in a patient receiving ustekinumab for refractory Crohn's disease","volume":"8","author":"Badat","year":"2014","journal-title":"J\u00a0Crohns Colitis"},{"issue":"1","key":"10.1016\/j.gtc.2017.05.013_bib54","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/MIB.0000000000000596","article-title":"Use of immunomodulators and biologics before, during, and after pregnancy","volume":"22","author":"McConnell","year":"2016","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"10.1016\/j.gtc.2017.05.013_bib55","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/bdrb.20250","article-title":"Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12\/23p40 monoclonal antibody, during pregnancy and lactation","volume":"89","author":"Martin","year":"2010","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"issue":"5","key":"10.1016\/j.gtc.2017.05.013_bib56","doi-asserted-by":"crossref","first-page":"AB178","DOI":"10.1016\/j.jaad.2014.01.740","article-title":"Pregnancy outcomes in women exposed to ustekinumab in the psoriasis clinical development program","volume":"70","author":"Schaufelberg","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.gtc.2017.05.013_bib57","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1016\/S0016-5085(16)30422-X","article-title":"437 Do infant serum levels of biologic agents at birth correlate with risk of adverse outcomes? Results from the PIANO registry","volume":"150","author":"Mahadevan","year":"2016","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.gtc.2017.05.013_bib58","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2015.12.003","article-title":"The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy","volume":"150","author":"Nguyen","year":"2016","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.gtc.2017.05.013_bib59","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11894-015-0465-x","article-title":"Update on the medical management of Crohn's disease","volume":"17","author":"Deepak","year":"2015","journal-title":"Curr Gastroenterol Rep"},{"issue":"6","key":"10.1016\/j.gtc.2017.05.013_bib60","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1053\/j.gastro.2013.10.047","article-title":"American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease","volume":"145","author":"Terdiman","year":"2013","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.gtc.2017.05.013_bib61","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/apt.13445","article-title":"Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease\u2014algorithm for practical management","volume":"43","author":"Ding","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.gtc.2017.05.013_bib62","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","article-title":"Review article: loss of response to anti-TNF treatments in Crohn's disease","volume":"33","author":"Ben-Horin","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.gtc.2017.05.013_bib63","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/ajg.2011.60","article-title":"Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review","volume":"106","author":"Billioud","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.gtc.2017.05.013_bib64","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.gtc.2017.05.013_bib65","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.gtc.2017.05.013_bib66","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.cgh.2016.05.023","article-title":"Biosimilars in inflammatory bowel disease: facts and fears of extrapolation","volume":"14","author":"Ben-Horin","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.gtc.2017.05.013_bib67","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/apt.13402","article-title":"Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases","volume":"42","author":"Papamichael","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.gtc.2017.05.013_bib68","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1136\/gutjnl-2012-302853","article-title":"Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-gamma-expressing Th1 cells and IL-17A\/IL-22-expressing Th17 cells and respond to anti-IL-12\/IL-23 antibody treatment","volume":"63","author":"Tillack","year":"2014","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.gtc.2017.05.013_bib69","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/ajg.2012.42","article-title":"Ustekinumab for peristomal pyoderma gangrenosum","volume":"107","author":"Fahmy","year":"2012","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.gtc.2017.05.013_bib70","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1016\/j.jaad.2012.04.045","article-title":"Severely recalcitrant pyoderma gangrenosum successfully treated with ustekinumab","volume":"67","author":"Goldminz","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.gtc.2017.05.013_bib71","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1001\/archdermatol.2011.168","article-title":"Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab","volume":"147","author":"Guenova","year":"2011","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.gtc.2017.05.013_bib72","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s10067-013-2469-y","article-title":"Involvement of IL-23 in enteropathic arthritis patients with inflammatory bowel disease: preliminary results","volume":"33","author":"Gheita","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.gtc.2017.05.013_bib73","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1097\/01.MIB.0000480260.28955.65","article-title":"The effect of vedolizumab on extraintestinal manifestations in patients with Crohn\u2019s disease in GEMINI 2","volume":"22","author":"Rubin","year":"2016","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"10.1016\/j.gtc.2017.05.013_bib74","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.jaad.2013.10.043","article-title":"Specific targeting of interleukin-23p19 as effective treatment for psoriasis","volume":"70","author":"Levin","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.gtc.2017.05.013_bib75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13555-015-0092-3","article-title":"A\u00a0review of biologic therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis","volume":"6","author":"Campa","year":"2016","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"10.1016\/j.gtc.2017.05.013_bib76","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cytogfr.2014.07.017","article-title":"IL-12-and IL-23 in health and disease","volume":"25","author":"Croxford","year":"2014","journal-title":"Cytokine Growth Factor Rev"},{"issue":"11","key":"10.1016\/j.gtc.2017.05.013_bib77","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1128\/IAI.00621-06","article-title":"Neutralization or absence of the interleukin-23 pathway does not compromise immunity to mycobacterial infection","volume":"74","author":"Chackerian","year":"2006","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.gtc.2017.05.013_bib78","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1128\/IAI.01329-06","article-title":"Interleukin-23 (IL-23)-IL-17 cytokine axis in murine Pneumocystis carinii infection","volume":"75","author":"Rudner","year":"2007","journal-title":"Infect Immun"},{"issue":"2","key":"10.1016\/j.gtc.2017.05.013_bib79","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.4049\/jimmunol.176.2.1098","article-title":"IL-23 enhances the inflammatory cell response in Cryptococcus neoformans infection and induces a cytokine pattern distinct from IL-12","volume":"176","author":"Kleinschek","year":"2006","journal-title":"J\u00a0Immunol"},{"issue":"3","key":"10.1016\/j.gtc.2017.05.013_bib80","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.4049\/jimmunol.173.3.1887","article-title":"IL-23 provides a limited mechanism of resistance to acute toxoplasmosis in the absence of IL-12","volume":"173","author":"Lieberman","year":"2004","journal-title":"J\u00a0Immunol"},{"issue":"4","key":"10.1016\/j.gtc.2017.05.013_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(15)30547-3","article-title":"830 Initial evaluation of MEDI2070 (specific Anti-IL-23 antibody) in patients with active Crohn's disease who have failed anti-TNF antibody therapy: a randomized, double-blind placebo-controlled phase 2A induction study","volume":"148","author":"Sands","year":"2015","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.gtc.2017.05.013_bib82","doi-asserted-by":"crossref","first-page":"S1266","DOI":"10.1016\/S0016-5085(16)34278-0","article-title":"812a Efficacy and safety of induction therapy with the selective IL-23 inhibitor BI 655066, in patients with moderate-to-severe Crohn\u2019s disease: results of a randomized, double-blind, placebo-controlled phase II study","volume":"150","author":"Feagan","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2017.05.013_bib83","series-title":"A\u00a0phase 2b double-blind, multi-dose, placebo-controlled study to evaluate the efficacy and safety of MEDI2070 in subjects with moderate to severe Crohn's disease who have failed or are intolerant to anti tumor necrosis factor-alpha therapy","author":"MedImmune LLC","year":"2000"},{"key":"10.1016\/j.gtc.2017.05.013_bib84","series-title":"An open label, single group, long term safety extension trial of BI\u00a0655066\/ABBV-066 (Risankizumab), in patients with moderately to severely active Crohn's disease","author":"AbbVie Inc","year":"2000"},{"key":"10.1016\/j.gtc.2017.05.013_bib85","series-title":"A\u00a0phase 2, multicenter, randomized, parallel-arm, placebo-controlled study of LY3074828 in subjects with active Crohn's disease (SERENITY)","author":"Eli Lilly and Company","year":"2000"},{"issue":"10080","key":"10.1016\/j.gtc.2017.05.013_bib86","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(17)30570-6","article-title":"Efficacy and safety of induction therapy with the selective IL-23 inhibitor risankizumab (BI 655066) in patients with moderate-to-severe Crohn\u2019s disease: a randomised, double-blind, placebo-controlled phase 2 study","volume":"389","author":"Feagan","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2017.05.013_bib87","series-title":"Enter into licensing agreement for tildrakizumab MC, Inc","author":"Sun Pharma and Merck & Co. Inc","year":"2014"},{"issue":"7","key":"10.1016\/j.gtc.2017.05.013_bib88","first-page":"438","article-title":"The present and future of inflammatory bowel disease treatment","volume":"12","author":"Sandborn","year":"2016","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2017.05.013_bib89","series-title":"Boehringer Ingelheim\u2019s investigational biologic cleared skin better, faster and for longer than ustekinumab in phase II psoriasis study","author":"Boehringer Ingelheim, Inc","year":"2015"},{"issue":"Suppl 10","key":"10.1016\/j.gtc.2017.05.013_bib90","article-title":"Efficacy and safety of different dose regimens of a selective IL-23p19 inhibitor (BI 655066) compared with ustekinumab in patients with moderate-to-severe plaque psoriasis with and without psoriatic arthritis","volume":"67","author":"Papp","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.gtc.2017.05.013_bib91","series-title":"A\u00a0study of guselkumab in participants with moderate to severe plaque-type psoriasis and an inadequate response to ustekinumab (NAVIGATE)","author":"Janssen Research & Development LLC","year":"2000"},{"issue":"4","key":"10.1016\/j.gtc.2017.05.013_bib92","first-page":"S130","article-title":"Long-term maintenance of radiological response is associated with decreased probability of surgeries, hospitalizations, and corticosteroids usage in Crohn's disease patients","volume":"150","author":"Deepak","year":"2016","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.gtc.2017.05.013_bib93","doi-asserted-by":"crossref","first-page":"S-589","DOI":"10.1016\/S0016-5085(11)62436-0","article-title":"Serum soluble IL2-receptor is increased in a subpopulation of Crohn\u2019s disease patients, who respond to open label use of ustekinumab, a human monoclonal antibody to IL-12\/23p40","volume":"140","author":"Kuehbacher","year":"2011","journal-title":"Gastroenterology"}],"container-title":["Gastroenterology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855317300675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855317300675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T07:55:23Z","timestamp":1692950123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889855317300675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":93,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0889855317300675"],"URL":"https:\/\/doi.org\/10.1016\/j.gtc.2017.05.013","relation":{},"ISSN":["0889-8553"],"issn-type":[{"value":"0889-8553","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gtc.2017.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}